FDA Calls For Class-Wide REMS For LABA Asthma Drugs

LABA asthma drugs are the latest group of medications to be hit with a class-wide Risk Evaluation and Mitigation Strategies requirement.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet